MissionIR Articles

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the release of study findings. Cybin sponsored the study, which…

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has completed dosing in part b of its three-part CYB004-E phase 1 trial.…

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced that its Chief Executive Officer Doug Drysdale will participate at the Oppenheimer 33rd Annual Health Care Conference taking…

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference; the title of the panel is…

Cybin (NEO: CYBN) (NYSE American: CYBN),a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its two lead clinical development programs: CYB003, a proprietary deuterated psilocybin analog for the potential treatment of major depressive…

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a strategic plan designed to streamline efforts, maximize operating efficiency and focus on critical clinical trials, including near-term, mid-term…

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its third quarter performance as well as recent business highlights; the report is for the period ended Dec.…

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received key approval to initiate human dosing of CYB004, its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, through a protocol amendment to…

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The…

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel (“Kernel”). The study…

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”)…

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health…

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today issued a year-end summary of its key milestone accomplishments in 2022. “2022 was a momentous year marked by steady…

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), announced that it presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (“ACNP”) annual…

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept. 30, 2022, as well as recent business highlights. “We…

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced progress on its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine (“DMT”). According to the update, dosing has been completed…

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor…

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and…

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its EMBARK Psychedelic-Assisted Psychotherapy Training Program have announced the graduation of highly skilled facilitators who are now prepared to handle…

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and…